EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Updated analysis of overall survival with imetelstat in relapsed/refractory myelofibrosis versus real-world data, and assessment of real-world treatment patterns

Andrew T. Kuykendall, Hana Qasim, Ghada Araji, Libo Sun, Qi Xia, Michelle Mudge-Riley, Joseph Eid, Rami S. Komrokji

Annals of Hematology · 11.11.2026

DOI: 10.1007/s00277-026-07350-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 11.11.2026. Verfasst von Andrew T. Kuykendall und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Geron Corporation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In a previous analysis of the phase 2 IMbark trial, imetelstat showed significantly longer median overall survival (mOS) in patients with Janus kinase inhibitor relapsed/refractory (R/R) intermediate-2–risk or high-risk myelofibrosis than in a closely matched real-world (RW) cohort treated with best available therapy (BAT) after ruxolitinib. Because the evolving myelofibrosis treatment landscape may influence outcomes, an updated OS analysis compared IMbark patients with a larger RW cohort after extended follow-up and explored changes in RW treatment patterns over this period. The RW dataset included 126 patients at Moffitt Cancer Center who discontinued ruxolitinib and received BAT between 2010 and 2025. Comparing treatment patterns for patients diagnosed before/after 2016 and 2019 showed significant reductions in the time from diagnosis to ruxolitinib initiation and in ruxolitinib treatment duration. Patients diagnosed after 2016/2019 had notably longer mOS than those diagnosed before 2016/2019. For the updated survival analysis between IMbark patients treated with imetelstat ( n = 59) and matched RW patients treated with BAT ( n = 54), median follow-up periods were 46.2 and 48.2 months, respectively. In the historical comparison of patients diagnosed before 2016, OS was longer among patients treated with imetelstat in IMbark than among those treated with BAT (mOS, 30.7 vs. 15.4 months; hazard ratio = 0.512; P =.003), with similar findings after propensity score adjustment. The significant improvement in OS among RW patients over the past decade may be attributable to shorter time to ruxolitinib initiation and earlier transitions to next-line therapies or clinical trials. Evolving treatment patterns are key considerations when interpreting future clinical trial outcomes. Trial registration ClinicalTrials.gov, NCT02426086 April 21, 2015.

Förderung

  • Geron Corporation

Zitieren

APA

Kuykendall, A. T., Qasim, H., Araji, G., Sun, L., Xia, Q., Mudge-Riley, M., Eid, J., & Komrokji, R. S. (2026). Updated analysis of overall survival with imetelstat in relapsed/refractory myelofibrosis versus real-world data, and assessment of real-world treatment patterns. Annals of Hematology. https://doi.org/10.1007/s00277-026-07350-0

Vancouver

Kuykendall AT, Qasim H, Araji G, Sun L, Xia Q, Mudge-Riley M, et al. Updated analysis of overall survival with imetelstat in relapsed/refractory myelofibrosis versus real-world data, and assessment of real-world treatment patterns. Annals of Hematology. 2026. doi:10.1007/s00277-026-07350-0

BibTeX
@article{Kuykendall2026,
  author = {Kuykendall, Andrew T. and Qasim, Hana and Araji, Ghada and Sun, Libo and Xia, Qi and Mudge-Riley, Michelle and Eid, Joseph and Komrokji, Rami S.},
  title = {Updated analysis of overall survival with imetelstat in relapsed/refractory myelofibrosis versus real-world data, and assessment of real-world treatment patterns},
  journal = {Annals of Hematology},
  year = {2026},
  doi = {10.1007/s00277-026-07350-0}
}
Kostenlos starten →